Prevention and treatment of osteoporosis in women

Current Obstetrics and Gynaecology

Volumn 15, Issue 4, 2005, Pages 251-258

  Brixen, Kim ^a   Abrahamsen, Bo ^b   Kassem, Moustapha ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b Koege Hospital   (Denmark)

Author keywords

Osteoporosis; Post menopausal; Prevention; Review; Therapy

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; CHLORIDE CHANNEL; CYPROTERONE ACETATE; ERGOCALCIFEROL; ESTRADIOL; ESTROGEN; ETIDRONIC ACID; GESTAGEN; HORMONE RECEPTOR STIMULATING AGENT; IBANDRONIC ACID; INTEGRIN; MEDROXYPROGESTERONE ACETATE; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARATHYROID HORMONE RECEPTOR; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; STRONTIUM RANELATE; TAMOXIFEN; UNINDEXED DRUG; VITAMIN D DERIVATIVE; VITAMIN K GROUP;

ABDOMINAL PAIN; BIOSYNTHESIS; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATABOLITE REPRESSION; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DYSPEPSIA; EROSION; ESOPHAGUS ULCER; EXERCISE; FALLING; FEVER; FLU LIKE SYNDROME; FLUSHING; FRAGILITY FRACTURE; HEARTBURN; HORMONE SUBSTITUTION; HUMAN; LEG CRAMP; LIFESTYLE; MEDICAL DOCUMENTATION; MOTIVATION; NAUSEA; NONHUMAN; NOSE IRRITATION; OSTEOSARCOMA; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK REDUCTION; SIDE EFFECT; SMOKING CESSATION; THROMBOEMBOLISM;

EID: 22744454875     PISSN: 09575847     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curobgyn.2005.05.003     Document Type: Article

References (13)

1. M. Kassem K. Brixen L. Mosekilde Ageing of the human skeleton and its contribution to osteoporotic fractures R. Aspinall Ageing of organs and systems 2003 Kluwer Academic Dordreeht
2. E. Seeman Pathogenesis of bone fragility in women and men Lancet 359 2002 1841 1850
3. L. Mosekilde Vitamin D and the elderly Clin Endocrinol (Oxford) 62 2005 265 281
4. V. Beral Breast cancer and hormone-replacement therapy in the Million Women Study Lancet 362 2003 419 427
5. J.E. Rossouw Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial J Am Med Assoc 288 2002 321 333
6. B. Ettinger Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators J Am Med Assoc 282 1999 637 645
7. S.R. Cummings Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial J Am Med Assoc 280 1998 2077 2082
8. M.R. McClung Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group N Engl J Med 344 2001 333 340
9. P.J. Meunier The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis N Engl J Med 350 2004 459 468
10. J.Y. Reginster Strontium ranelate reduces the risk of nonvertebral fractures in post-menopausal women with osteoporosis: TROPOS study J Clin Endocrinol Metab 2005
11. K.T. Brixen Teriparatide (biosynthetic human parathyroid hormone 1–34): a new paradigm in the treatment of osteoporosis Basic Clin Pharmacol Toxicol 94 2004 260 270
12. R.M. Neer Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 2001 1434 1441
13. P.M. Christensen K. Brixen I.S. Kristiansen Danish Osteoporosis Outcome Model (DOOM) 2003 University of Southern Denmark, Department of Health Economics Denmark